Humalog insulin lispro

Forced formulary switches to biosimilar Admelog are the single biggest driver of patient rage and adherence breakdown; this is the commercial battleground Lilly must own proactively.

• Insurance-forced substitution to Admelog or rival analogs is the dominant negative experience, generating the loudest patient voices and the highest abandonment risk in this corpus.
• KwikPen mechanical failures (jamming, dose-shorting, wasted units) are a discrete, brand-damaging complaint that is independent of the molecule itself and fully actionable by the device team.
• When patients have stable, uninterrupted Humalog access, A1C transformation stories (e.g., 13.2 to 6.0) generate powerful positive word-of-mouth that drives peer trust.
• Slow or variable onset timing is the top dosing-education gap, with CGM-wearing pump patients expecting 15-minute action but frequently observing 45 to 60 minute delays, creating dangerous pre-bolus confusion.